trial · primary record
Obrixtamig
Small Cell Lung Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2030-04-26 |
| Primary endpoint | Part 1: The occurrence of dose limiting toxicities (DLTs) during the DLT evaluation period |
| Registry ID | NCT07707895 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:44.866Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07707895
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.